Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
SANA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $7.30
Previous CloseN/A
Volume118.31M
Average Volume (3M)5.60M
Market Cap
$833.02M
Enterprise Value$659.48M
Total Cash (Recent Filing)$72.67M
Total Debt (Recent Filing)$85.49M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 05, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding258,702,030
10 Day Avg. Volume4,757,974
30 Day Avg. Volume5,595,784
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue43.15
Enterprise Value/Gross Profit907.12
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$10.00Price Target Upside210.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial StabilitySana enters a well-capitalized position to execute its program development goals after raises that accumulated approximately $105M.
Regulatory ProgressThe positive feedback from the FDA INTERACT meeting substantially raises the probability of success for the company's program.
Scientific AdvancementsThe HIP-modified islet cells were found to have evaded both the adaptive and innate immune systems with no safety issues, signifying a major positive outcome.
Bears Say
Dependence On Future DevelopmentsSana has guided to a near-term regulatory interaction to ensure FDA alignment that the master cell bank meets requirements for quality and stability, which will be important for better defining timelines to IND filing.
Financial PerformanceSana reported a GAAP net loss of $93.8MM.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.26 and its highest was $7.30 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $833.02M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Aug 11, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.201 by -$0.189.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.18.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 258,702,030 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.201. Following the earnings report the stock price went up 6.507%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
Sana Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (210.56% Upside)
$10.00 (210.56% Upside)
Blogger Sentiment
Bullish
SANA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 566.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.86%
12-Months-Change
Fundamentals
Return on Equity
-109.12%
Trailing 12-Months
Asset Growth
-41.54%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology (SANA) is a leading biotechnology company focused on developing and delivering engineered cells as medicines for patients. Operating within the biotechnology and pharmaceutical sectors, Sana specializes in advancing in vivo and ex vivo cell engineering platforms with the goal of treating a range of diseases including cancer, genetic disorders, and other serious illnesses. The company's core technologies aim to repair or control genes and replace damaged cells with healthy ones, offering innovative solutions that address unmet medical needs.
SANA Stock 12 Month Forecast
Average Price Target
$10.00
▲(210.56% Upside)
Technical Analysis
Dianthus Therapeutics
―
Autolus Therapeutics
―
Xeris Pharmaceuticals
―
Tectonic Therapeutic
―
Hyrecar
―
Ownership Overview
30.53% Insiders
16.79% Mutual Funds
0.07% Other Institutional Investors
45.72% Public Companies and
Individual Investors